Several therapeutic applications are now being studied in preclinical tests using induced pluripotent stem cell (iPSC) derived cells for their potential to produce functional cells capable of replacing damaged or dysfunctional tissues in patients. The first clinical trial using iPSCs started in 2008, and now in 2020, the number has risen to 53.
The early clinical trials did not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines were created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. [Read more…]